- Article
Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021
- Marya D. Zilberberg,
- Brian H. Nathanson,
- Mark A. Redell,
- Kate Sulham and
- Andrew F. Shorr
Background/Objectives: Meropenem–vaborbactam (MEV) and ceftazidime–avibactam (CZA) are active against “urgent threat” pathogens like carbapenem-resistant Enterobacterales (CRE). However, few studies have compared outcomes betw...